Tanshinone IIA Modulates Low Density Lipoprotein Uptake via Down-Regulation of PCSK9 Gene Expression in HepG2 Cells

doi:10.1371/journal.pone.0162414

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 生物科技系(所) > 期刊論文 > Item 310902800/31064

請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/31064

標題:	Tanshinone IIA Modulates Low Density Lipoprotein Uptake via Down-Regulation of PCSK9 Gene Expression in HepG2 Cells
作者:	Chen, Hung-Chen Chen, Pei-Yi Wu, Ming-Jiuan Tai, Mi-Hsueh Yen, Jui-Hung
貢獻者:	Tzu Chi Univ, Dept Mol Biol & Human Genet Buddhist Tzu Chi Gen Hosp, Ctr Med Genet Chia Nan Univ Pharm & Sci, Dept Biotechnol
關鍵字:	ldl receptor target genes cholesterol homeostasis transcription factor oxidative stress degradation disease binding model mice
日期:	2016-09
上傳時間:	2018-01-18 11:40:56 (UTC+8)
出版者:	Public Library Science
摘要:	Tanshinone IIA, one of the most pharmacologically bioactive phytochemicals isolated from Salvia miltiorrhiza Bunge, possesses several biological activities such as anti-inflammation, anti-cancer, neuroprotection and hypolipidemic activities. In this study, we aim to investigate the hypocholesterolemic effect of tanshinone IIA in hepatic cells. We demonstrated that tanshinone IIA significantly increased the amount of low-density lipoprotein receptor (LDLR) and LDL uptake activity in HepG2 cells at the post-transcriptional regulation. We further demonstrated that tanshinone IIA inhibited the expression of proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA and mature protein, which may lead to an increase the cell-surface LDLR in hepatic cells. We further identified a regulatory DNA element involved in the tanshinone IIA-mediated PCSK9 down-regulation, which is located between the -411 and -336 positions of the PCSK9 promoter. Moreover, we found that tanshinone IIA markedly increased the nuclear forkhead box O3a (FoxO3a) level, enhanced FoxO3a/PCSK9 promoter complexes formation and decreased the PCSK9 promoter binding capacity of hepatocyte nuclear factor 1 alpha (HNF-1 alpha), resulting in suppression of PCSK9 gene expression. Finally, we found that the statin-induced PCSK9 overexpression was attenuated and the LDLR activity was elevated in a synergic manner by combination of tanshinone IIA treatment in HepG2 cells. Overall, our results reveal that the tanshinone IIA modulates LDLR level and activity via down-regulation of PCSK9 expression in hepatic cells. Our current findings provide a molecular basis of tanshinone IIA to develop PCSK9 inhibitors for cholesterol management.
關聯:	Plos One, v.11 n.9, e0162414
顯示於類別:	[生物科技系(所)] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
31064.pdf		5532Kb	Adobe PDF	343	檢視/開啟
index.html		0Kb	HTML	1293	檢視/開啟

在CNU IR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....